NONOF
Price
$57.98
Change
+$0.48 (+0.83%)
Updated
Oct 14 closing price
Capitalization
257.85B
Intraday Buy/Sell Signals
NVO
Price
$56.77
Change
+$0.11 (+0.19%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
257.85B
20 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

NONOF vs NVO

Header iconNONOF vs NVO Comparison
Open Charts NONOF vs NVOBanner chart's image
Novo-Nordisk A/S
Price$57.98
Change+$0.48 (+0.83%)
Volume$13.54K
Capitalization257.85B
Novo-Nordisk A/S
Price$56.77
Change+$0.11 (+0.19%)
Volume$6.29K
Capitalization257.85B
NONOF vs NVO Comparison Chart in %
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NONOF vs. NVO commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NONOF is a Hold and NVO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (NONOF: $57.98 vs. NVO: $56.66)
Brand notoriety: NONOF and NVO are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NONOF: 5% vs. NVO: 52%
Market capitalization -- NONOF: $257.85B vs. NVO: $257.85B
NONOF [@Pharmaceuticals: Major] is valued at $257.85B. NVO’s [@Pharmaceuticals: Major] market capitalization is $257.85B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $728.24B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $93.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NONOF’s FA Score shows that 2 FA rating(s) are green whileNVO’s FA Score has 2 green FA rating(s).

  • NONOF’s FA Score: 2 green, 3 red.
  • NVO’s FA Score: 2 green, 3 red.
According to our system of comparison, both NONOF and NVO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NONOF’s TA Score shows that 5 TA indicator(s) are bullish while NVO’s TA Score has 5 bullish TA indicator(s).

  • NONOF’s TA Score: 5 bullish, 5 bearish.
  • NVO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both NONOF and NVO are a good buy in the short-term.

Price Growth

NONOF (@Pharmaceuticals: Major) experienced а -1.74% price change this week, while NVO (@Pharmaceuticals: Major) price change was -4.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.26%. For the same industry, the average monthly price growth was +1.28%, and the average quarterly price growth was +19.09%.

Reported Earning Dates

NVO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.26% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NONOF($258B) and NVO($258B) have the same market capitalization . NONOF (14.96) and NVO (14.62) have similar P/E ratio . NVO (-32.315) and NONOF (-32.496) have similar YTD gains . NONOF (154B) and NVO (154B) have comparable annual earnings (EBITDA) . NONOF (18.9B) and NVO (18.9B) have equal amount of cash in the bank . NONOF (99.3B) and NVO (99.3B) have identical debt. NONOF (312B) and NVO (312B) have equivalent revenues.
NONOFNVONONOF / NVO
Capitalization258B258B100%
EBITDA154B154B100%
Gain YTD-32.496-32.315101%
P/E Ratio14.9614.62102%
Revenue312B312B100%
Total Cash18.9B18.9B100%
Total Debt99.3B99.3B100%
FUNDAMENTALS RATINGS
NONOF vs NVO: Fundamental Ratings
NONOF
NVO
OUTLOOK RATING
1..100
267
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
16
Undervalued
PROFIT vs RISK RATING
1..100
8079
SMR RATING
1..100
1515
PRICE GROWTH RATING
1..100
6363
P/E GROWTH RATING
1..100
9797
SEASONALITY SCORE
1..100
n/a5

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVO's Valuation (16) in the Pharmaceuticals Major industry is in the same range as NONOF (17) in the null industry. This means that NVO’s stock grew similarly to NONOF’s over the last 12 months.

NVO's Profit vs Risk Rating (79) in the Pharmaceuticals Major industry is in the same range as NONOF (80) in the null industry. This means that NVO’s stock grew similarly to NONOF’s over the last 12 months.

NVO's SMR Rating (15) in the Pharmaceuticals Major industry is in the same range as NONOF (15) in the null industry. This means that NVO’s stock grew similarly to NONOF’s over the last 12 months.

NVO's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as NONOF (63) in the null industry. This means that NVO’s stock grew similarly to NONOF’s over the last 12 months.

NVO's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as NONOF (97) in the null industry. This means that NVO’s stock grew similarly to NONOF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NONOFNVO
RSI
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
64%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
63%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
70%
MACD
ODDS (%)
Bearish Trend 3 days ago
58%
Bearish Trend 3 days ago
58%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 3 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
68%
Advances
ODDS (%)
Bullish Trend 11 days ago
76%
Bullish Trend 11 days ago
67%
Declines
ODDS (%)
Bearish Trend 21 days ago
64%
Bearish Trend 7 days ago
59%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
58%
Bearish Trend 3 days ago
52%
Aroon
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HALO66.651.32
+2.02%
Halozyme Therapeutics
WYY5.700.07
+1.24%
WidePoint Corp
NEXT6.180.07
+1.06%
NextDecade Corp
TSM295.94-6.95
-2.29%
Taiwan Semiconductor Manufacturing Company Ltd
VALU38.80-1.20
-3.00%
Value Line

NONOF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NONOF has been closely correlated with NVO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NONOF jumps, then NVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NONOF
1D Price
Change %
NONOF100%
+0.84%
NVO - NONOF
70%
Closely correlated
-1.46%
LABFF - NONOF
23%
Poorly correlated
N/A
IMRN - NONOF
22%
Poorly correlated
-1.44%
QSI - NONOF
21%
Poorly correlated
+3.37%
VRTX - NONOF
21%
Poorly correlated
+1.19%
More

NVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVO has been closely correlated with NONOF. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVO jumps, then NONOF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVO
1D Price
Change %
NVO100%
-1.46%
NONOF - NVO
70%
Closely correlated
+0.84%
TECH - NVO
36%
Loosely correlated
-0.60%
GMAB - NVO
35%
Loosely correlated
+0.22%
MRK - NVO
34%
Loosely correlated
-1.17%
BCAB - NVO
33%
Loosely correlated
-11.60%
More